Enlivex Therapeutics Ltd Total Liabilities
Enlivex Therapeutics Ltd total liabilities. Based on the latest financial reports, Enlivex Therapeutics Ltd (ENLV) has total liabilities worth ILA3.46 Million ILA (≈ $9.27K USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ENLV financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Enlivex Therapeutics Ltd (2012–2024)
Total liabilities of Enlivex Therapeutics Ltd from 2012 to 2024. This chart illustrates how Enlivex Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Enlivex Therapeutics Ltd (ENLV) long-term investment share to see how much of total assets are deployed in long-term investments.
Enlivex Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Enlivex Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SCANDIN.ENVIRO SYSTEMS AB
F:1HR
|
Germany | €34.88 Million |
|
Arcontech Group Plc
LSE:ARC
|
UK | GBX2.17 Million |
|
Greenroc Mining PLC
LSE:GROC
|
UK | GBX2.85 Million |
|
Safe Orthopaedics SA
PA:ALSAF
|
France | €22.49 Million |
|
Airea Plc
LSE:AIEA
|
UK | GBX9.75 Million |
|
Haydale Graphene Industries
LSE:HAYD
|
UK | GBX6.69 Million |
|
Biosergen AS
ST:BIOSGN
|
Sweden | Skr13.04 Million |
|
FiscalNote Holdings Inc.
NYSE:NOTE
|
USA | $188.64 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Enlivex Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Enlivex Therapeutics Ltd total assets.
Liquidity & Leverage Metrics
Enlivex Therapeutics Ltd Total Liabilities Ratios Explained
Enlivex Therapeutics Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Enlivex Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Enlivex Therapeutics Ltd (2012–2024)
The table below shows the annual total liabilities of Enlivex Therapeutics Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ILA4.10 Million ≈ $10.99K |
-39.26% |
| 2023-12-31 | ILA6.75 Million ≈ $18.09K |
-37.53% |
| 2022-12-31 | ILA10.80 Million ≈ $28.96K |
+6.87% |
| 2021-12-31 | ILA10.11 Million ≈ $27.10K |
+107.49% |
| 2020-12-31 | ILA4.87 Million ≈ $13.06K |
-22.41% |
| 2019-12-31 | ILA6.28 Million ≈ $16.83K |
+372.74% |
| 2018-12-31 | ILA1.33 Million ≈ $3.56K |
+188.70% |
| 2017-12-31 | ILA460.00K ≈ $1.23K |
-76.18% |
| 2016-12-31 | ILA1.93 Million ≈ $5.18K |
-25.27% |
| 2015-12-31 | ILA2.58 Million ≈ $6.93K |
+13.33% |
| 2014-12-31 | ILA2.28 Million ≈ $6.11K |
+1640.46% |
| 2013-12-31 | ILA131.00K ≈ $351.21 |
+61.73% |
| 2012-12-31 | ILA81.00K ≈ $217.16 |
-- |
About Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee o… Read more